Physician profile
Stephen M Soll
NPI 1114924701
$3,508.88
in general payments reported to CMS, 2019-2025
22 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $133 · 2021: $339 · 2022: $2,026 · 2023: $179 · 2024: $179 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,562.56 | 2022 | |
| Alcon Vision LLC | $357.36 | 2022-2025 | Argos, Clareon Panoptix Pro, Tryptyr |
| Horizon Therapeutics Plc | $229.91 | 2021-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $222.66 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $221.74 | 2019-2025 | |
| Oyster Point Pharma, INC. | $182.87 | 2022-2024 | Tyrvaya, Ryzumvi |
| Merz Pharmaceuticals, LLC | $100.65 | 2021-2025 | Xeomin |
| Bausch & Lomb Americas INC. | $95.47 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $85.71 | 2019-2022 | |
| Amgen INC. | $84.02 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $57.05 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $54.44 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Harrow Eye, LLC | $52.20 | 2025 | Vevye |
| Shire North American Group INC | $41.63 | 2019 | |
| Abbvie INC. | $28.99 | 2022-2023 | Lumigan, Alphagan P, Vuity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $22.38 | 2022 | |
| Tearlab Corp | $21.39 | 2021 | |
| Boston Scientific Corporation | $19.55 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $18.17 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Soll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.